Cells treated with TGFβ did not exhibit changes in activation of proteins connected to cancer progression and involved in the mitogen-activated protein kinase (MAPK) pathway, which abnormal regulation may lead to increased or uncontrolled cell proliferation and resistance to apoptosis of cancer cells. This evidence concerns the gene TGFB1 and cancer.